Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - QUIDEL CORP /DE/ | a58900e8vk.htm |
| EX-10.2 - EX-10.2 - QUIDEL CORP /DE/ | a58900exv10w2.htm |
Exhibit 10.1
2011 Equity Incentive Plan
The 2011 Equity Incentive Plan provides for the issuance of equity incentive awards in the form of
(i) non-qualified stock options; and (ii) performance-based restricted stock units.
| Performance-Based | ||||||||
| Restricted Stock Units | Non-Qualified Stock | |||||||
| Executive Officer | (# shares) | Options (# shares) | ||||||
Douglas C. Bryant President and Chief Executive Officer |
28,639 | 85,918 | ||||||
Robert J. Bujarski Senior Vice President, Business Development and General Counsel |
10,000 | 30,000 | ||||||
Scot M. McLeod Senior Vice President, Operations |
8,333 | 20,000 | ||||||
John M. Radak Chief Financial Officer |
8,333 | 20,000 | ||||||
David Scholl Senior Vice President, Commercial Operations |
8,333 | 25,000 | ||||||
Timothy T. Stenzel Chief Scientific Officer |
10,000 | 30,000 | ||||||
John D. Tamerius
Senior Vice President, Clinical and Regulatory Affairs |
8,333 | 25,000 | ||||||
The vesting period for the non-qualified stock options is four years with the first 50% of such
stock options vesting at the end of the second-year anniversary of the grant date and the remainder
vesting 25% annually thereafter. Vesting for the performance-based restricted stock units has a
three-year cliff and is tied to achievement of a performance metric of compounded annual growth
rate in earnings-per-share (EPS) in 2013 compared to a baseline EPS determined by the Compensation
Committee for 2010. In addition, in the event that the Company achieves certain elevated
performance metrics prior to the end of the three-year vesting period (defined by the Compensation
Committee with pre-determined elevated EPS targets in either 2011 or 2012), the performance-base
restricted stock units will be deemed to have met the performance requirements and will convert to
time-based vesting for the remainder of the three-year term.